Galapagos Details Strategic Transformation Initiatives
Company Focuses on Future Opportunities Following Cell Therapy Review
Galapagos NV (Euronext & NASDAQ: GLPG) has publicly declared its plans to discontinue its cell therapy business, a decision following an extensive strategic assessment. The leadership believes that this move represents the most effective allocation of resources to ensure a brighter and more sustainable future for the company.
This strategic decision allows Galapagos to streamline operations while reallocating cash resources towards developing novel therapeutics through innovative partnerships and business development ventures.
Leadership Insights on the Transformation
Henry Gosebruch, the CEO of Galapagos, emphasized the importance of this decision, stating, “After thoroughly reviewing our options, we recognized that there were no feasible offers for the cell therapy segment that could sustain its viability. Our review revealed significant investment demands coupled with shifting market conditions. We concluded that focusing our efforts and investments on unmet medical needs would be more beneficial for our stakeholders.”
With this assessment in mind, the decision to wind down the cell therapy division has been made in gratitude to all the staff, clinical investigators, patients, and shareholders who have been involved throughout this journey.
Implications for Employees and Operations
The Board of Directors unanimously endorsed this decision, aside from the two Directors appointed by Gilead, who recused themselves from voting due to potential conflicts of interest. Before implementing this plan, Galapagos will consult with its works councils in Belgium and the Netherlands, ensuring transparent communication as the business transitions.
The wind-down is expected to affect approximately 365 employees located in various regions, including Europe, the U.S., and China. Closure plans include the sites in Leiden (Netherlands), Basel (Switzerland), Princeton, Pittsburgh (U.S.), and Shanghai (China). However, the core operations of Galapagos will continue, with a dedicated team at the headquarters in Mechelen, Belgium, focused on driving long-term growth and development.
Financial Projections and Future Outlook
If the decision to finalize the wind down is confirmed, Galapagos anticipates incurring significant costs associated with this transition. Estimated operational expenditures might reach between €100 million to €125 million from the fourth quarter of 2025 through 2026. Additionally, restructuring costs could range from €150 million to €200 million in 2026.
The company is set to provide an updated cash outlook along with its third-quarter earnings, offering further transparency to investors and stakeholders about its financial position.
Ongoing Business Development and Legal Guidance
Throughout this process, Galapagos is being guided by reputable legal and financial advisors, including Paul Weiss, Linklaters, Rutgers & Posch for legal matters and Morgan Stanley & Co. International plc for financial advice. This support ensures that the transformation is handled proficiently and strategically.
As Galapagos embarks on this transformative era, its commitment to advancing health solutions remains strong, focusing on impactful collaborations to expand its pipeline of therapeutics.
Frequently Asked Questions
What prompted Galapagos to wind down its cell therapy business?
The decision was influenced by a comprehensive strategic review showing no viable offers to sustain the cell therapy operations.
How many employees will the wind down decision affect?
Approximately 365 employees across Europe, the U.S., and China are expected to be impacted by this decision.
What are the anticipated costs associated with the wind down?
Galapagos estimates operational costs of €100 million to €125 million from Q4 2025 through 2026 and one-time restructuring costs between €150 million and €200 million in 2026.
Will the company continue other business operations?
Yes, Galapagos plans to maintain its non-cell therapy activities and focus on transformative business development projects.
Who is advising Galapagos through this transition?
Galapagos is being advised by Paul Weiss, Linklaters, and Morgan Stanley & Co. International plc during this transitional phase.
